PSA density improves the rate of prostate cancer detection in Chinese men with a PSA between 2.5-10.0 ng ml (-1) and 10.1-20.0 ng ml (-1) : a multicenter study
- PMID: 25475661
- PMCID: PMC4430959
- DOI: 10.4103/1008-682X.142129
PSA density improves the rate of prostate cancer detection in Chinese men with a PSA between 2.5-10.0 ng ml (-1) and 10.1-20.0 ng ml (-1) : a multicenter study
Abstract
Chinese men should have a higher prostate-specific antigen (PSA) "gray zone" than the traditional value of 2.5-10.0 ng ml-1 since the incidence of prostate cancer (PCa) in Chinese men is relative low. We hypothesized that PSA density (PSAD) could improve the rate of PCa detection in Chinese men with a PSA higher than the traditional PSA "gray zone." A total of 461 men with a PSA between 2.5 and 20.0 ng ml-1 , who had undergone prostatic biopsy at two Chinese centers were included in the analysis. The men were then further divided into groups with a PSA between 2.5-10.0 ng ml-1 and 10.1-20.0 ng ml-1 . Receiver operating characteristic (ROC) curve was used to evaluate the efficacy of PSA and PSAD for the diagnosis of PCa. In men with a PSA of 2.5-10.0 ng ml-1 or 10.1-20.0 ng ml-1 , the areas under the ROC curve were higher for PSAD than for PSA. This was consistent across both centers and the cohort overall. When the entire cohort was considered, the optimal PSAD cut-off for predicting PCa in men with a PSA of 2.5-10.0 ng ml-1 was 0.15 ng ml-1 ml-1 , with a sensitivity of 64.4% and specificity of 64.6%. The optimal cut-off for PSAD in men with a PSA of 10.1-20.0 ng ml-1 was 0.33 ng ml-1 ml-1 , with a sensitivity of 60.3% and specificity of 82.7%. PSAD can improve the effectiveness for PCa detection in Chinese men with a PSA of 2.5-10.0 ng ml-1 (traditional Western PSA "gray zone") and 10.1-20.0 ng ml-1 (Chinese PSA "gray zone").
Figures


Similar articles
-
Peripheral zone PSA density: a predominant variable to improve prostate cancer detection efficiency in men with PSA higher than 4 ng ml-1.Asian J Androl. 2021 Jul-Aug;23(4):415-420. doi: 10.4103/aja.aja_72_20. Asian J Androl. 2021. PMID: 33473011 Free PMC article.
-
Transition zone PSA density improves the prostate cancer detection rate both in PSA 4.0-10.0 and 10.1-20.0 ng/ml in Chinese men.Urol Oncol. 2013 Aug;31(6):744-8. doi: 10.1016/j.urolonc.2011.06.012. Epub 2011 Aug 24. Urol Oncol. 2013. PMID: 21868261
-
Percent free prostate-specific antigen does not improve the effectiveness of prostate cancer detection in Chinese men with a prostate-specific antigen of 2.5-20.0 ng/ml: a multicenter study.Med Oncol. 2014 Apr;31(4):925. doi: 10.1007/s12032-014-0925-4. Epub 2014 Mar 23. Med Oncol. 2014. PMID: 24659324
-
Early prostate-specific antigen changes and the diagnosis and prognosis of prostate cancer.Curr Opin Urol. 2009 May;19(3):221-6. doi: 10.1097/MOU.0b013e32832a2d10. Curr Opin Urol. 2009. PMID: 19318948 Free PMC article. Review.
-
PSA, an outdated biomarker for prostate cancer: In search of a more specific biomarker, citrate takes the spotlight.J Steroid Biochem Mol Biol. 2024 Oct;243:106588. doi: 10.1016/j.jsbmb.2024.106588. Epub 2024 Jul 19. J Steroid Biochem Mol Biol. 2024. PMID: 39025336 Review.
Cited by
-
Using clinical parameters to predict prostate cancer and reduce the unnecessary biopsy among patients with PSA in the gray zone.Sci Rep. 2020 Mar 20;10(1):5157. doi: 10.1038/s41598-020-62015-w. Sci Rep. 2020. PMID: 32198373 Free PMC article.
-
Integration of PSAd and multiparametric MRI to forecast biopsy outcomes in biopsy-naïve patients with PSA 4~20 ng/ml.Front Oncol. 2024 Jul 4;14:1413953. doi: 10.3389/fonc.2024.1413953. eCollection 2024. Front Oncol. 2024. PMID: 39026982 Free PMC article.
-
Clinical application of free/total PSA ratio in the diagnosis of prostate cancer in men over 50 years of age with total PSA levels of 2.0-25.0 ng ml-1 in Western China.Asian J Androl. 2022 Mar-Apr;24(2):195-200. doi: 10.4103/aja202182. Asian J Androl. 2022. PMID: 34916475 Free PMC article.
-
Prebiopsy bpMRI and hematological parameter-based risk scoring model for predicting outcomes in biopsy-naive men with PSA 4-20 ng/mL.Sci Rep. 2022 Dec 19;12(1):21895. doi: 10.1038/s41598-022-26242-7. Sci Rep. 2022. PMID: 36536031 Free PMC article.
-
PSA density in the diagnosis of prostate cancer in the Chinese population: results from the Chinese Prostate Cancer Consortium.Asian J Androl. 2021 May-Jun;23(3):300-305. doi: 10.4103/aja.aja_61_20. Asian J Androl. 2021. PMID: 33208562 Free PMC article.
References
-
- Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9–29. - PubMed
-
- Matsuda T, Saika K. Comparison of time trends in prostate cancer incidence (1973-2002) in Asia, from cancer incidence in five continents, Vols IV-IX. Jpn J Clin Oncol. 2009;39:468–9. - PubMed
-
- Yoshida K, Honda M, Sumi S, Arai K, Suzuki S, et al. Levels of free prostate-specific antigen (PSA) can be selectively measured by heat treatment of serum: free/total-PSA ratios improve detection of prostate carcinoma. Clin Chim Acta. 1999;280:195–203. - PubMed
-
- Benson MC, Whang IS, Pantuck A, Ring K, Kaplan SA, et al. Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. J Urol. 1992;147:815–6. - PubMed
-
- Benson MC, Whang IS, Olsson CA, McMahon DJ, Cooner WH. The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen. J Urol. 1992;147:817–21. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous